复发性转移性甲状腺髓样癌:长期生长抑素类似物治疗持续缓解一例
一例64岁男性甲状腺髓样癌患者,2010年行全甲状腺切除及颈清扫(IVA期,pT2pN1bM0,R1)并辅助放化疗,2012年出现肾上腺、十二指肠及胰腺转移,无法 salvage 手术,自2012年9月起接受Somatuline Autogel® 120 mg每28天皮下注射,11个月后降钙素与CEA均正常化,CT示转移灶消失或明显缩小,持续缓解至2016年2月发现新发右肾上腺、右肺上叶结节及腹腔干淋巴结,降钙素轻度升至47 pg/mL,CEA与降钙素仍正常。作者认为长期生长抑素类似物可能对复发后无症状、低肿瘤负荷且Octreoscan阳性的病例有益,需更多数据确认。
要点
- 转移性甲状腺髓样癌术后复发,Somatuline Autogel® 120 mg每28天皮下注射11个月后降钙素与CEA正常化。
- 影像学示肾上腺、十二指肠及胰腺转移灶消失或明显缩小,持续缓解近3.5年。
- 作者认为长期生长抑素类似物可能对无症状、低肿瘤负荷且Octreoscan阳性的复发病例有益。
核心结论
- 长期生长抑素类似物治疗使一例根治性术后复发转移性甲状腺髓样癌患者获得持续肿瘤缓解,为文献中少数此类病例之一。
- 作者认为 prolonged treatment with somatostatin analogues may be beneficial in asymptomatic cases with a low tumor burden and a positive Octreoscan following recurrence。
- 作者指出需更多数据确认上述发现。
研究设计与样本
- 病例报告:一例64岁男性甲状腺髓样癌患者。
- 2010年1月诊断,行全甲状腺切除及颈清扫(IVA期,pT2pN1bM0,R1),术后辅助局部区域放疗。
主要发现
- 2012年1月出现复发转移,CEA与降钙素升高,Octreoscan®示右肾上腺及胰头阳性摄取,CT示右肾上腺、十二指肠球部及两个胰腺病灶,超声内镜及细胞学证实为转移,排除 salvage 手术。
- 2012年9月起予Somatuline Autogel® 120 mg每28天皮下注射,11个月后降钙素与CEA均正常化,新CT示转移灶消失或明显缩小。
- 2014年1月Octreoscan及2014年2月增强CT示肿瘤持续缓解。
- 至2016年2月新Octreoscan示右肾上腺、右肺上叶结节及腹腔干淋巴结复发,CEA与降钙素仍正常,降钙素轻度升高至47 pg/mL。
- 自开始生长抑素类似物治疗起持续缓解近3.5年。
临床怎么用
- 作者认为,对于复发后无症状、肿瘤负荷低且Octreoscan阳性的病例,长期生长抑素类似物治疗可能有益。
局限性
- 作者指出需更多数据确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Medullary thyroid carcinoma (MTC) is a rare disease. Treatment options for recurrent disease are limited. Although somatostatin analogues might have a role as anticancer agents in MTC, the evidence is inconclusive. PATIENT FINDINGS: A 64-year-old male was diagnosed with MTC in January 2010. Total thyroidectomy with neck dissection (stage IVA, pT2pN1bM0, R1) was performed, followed by adjuvant locoregional radiotherapy. Two years later, in January 2012, the patient developed recurrent metastatic disease, evidenced by elevated carcinoembryonic antigen (CEA) and calcitonin levels, and a positive uptake (Octreoscan®) in the right adrenal gland and pancreatic head. A further computed tomography (CT) scan revealed metastases in the right adrenal gland, the duodenal bulb, and two pancreatic lesions, which were later confirmed as metastases by endoscopic ultrasound and cytology, and therefore salvage surgery was ruled out. Treatment with Somatuline Autogel® (120 mg subcutaneously every 28 days) was initiated in September 2012, and 11 months later, calcitonin and CEA levels had both normalized, and a new CT scan showed that the metastatic lesions had disappeared or shrunk markedly. An Octreoscan performed in January 2014 and a repeat contrast-enhanced CT in February 2014 showed sustained tumor response. The patient remained in remission until February 2016, when a new Octreoscan revealed recurrent disease in the right adrenal gland, a nodule in the right upper pulmonary lobe, and nodal disease in the celiac trunk. CEA and calcitonin levels remained normal, although with a slight increase in calcitonin levels (47 pg/mL). SUMMARY: The unusual case is described of a patient with metastatic MTC involving the adrenal gland, duodenum, and pancreas, who achieved a sustained response to somatostatin analogues after 11 months of treatment. The patient remained in remission for nearly 3.5 years from initiation of treatment with somatostatin analogues. CONCLUSIONS: The case presented here is one of the few described in the literature in which long-term treatment with somatostatin analogues resulted in a sustained tumor response in a patient with metastatic recurrent MTC following curative-intent surgery. These findings suggest that prolonged treatment with somatostatin analogues may be beneficial in asymptomatic cases with a low tumor burden and a positive Octreoscan following recurrence. More data are needed to confirm these findings.
引用
- Cano JM, Galán R, López R, et al. Recurrent Metastatic Medullary Thyroid Carcinoma: A Case of Sustained Response to Prolonged Treatment with Somatostatin Analogues. Thyroid. 2017. PMID: 28927353. doi:10.1089/thy.2016.0540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。